Tomorrow we are going to learn the details behind two major cardiology outcome trials that failed:
HORIZON targeting Lp(a)
ZEUS targeting IL-6 and hsCRP
Quoted from the original post:
This is why you should want to see more than improved bloodwork before calling a treatment a success.
In ZEUS, a drug lowered inflammation markers [IL-6 & hsCRP] in people with cardiovascular and kidney disease, but didn’t significantly reduce their combined risk of heart attack, stroke or cardiovascular death.
That distinction matters well beyond this trial. In health and longevity, we spend a lot of time tracking numbers. The harder question is whether changing those numbers actually improves someone’s health.
I’m watching Saturday’s (tomorrow's) American Heart Association presentation closely. The headline results are already public, but the presentation will provide more clarity.
Selected references:
- CANTOS: PMID: 28845751
- ZEUS: Novo Nordisk company announcement 45/2026



